Medicare Enrolled
Dr. Viralkumar Bhanderi, M.D.
Medical Oncology · Tallahassee, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Bhanderi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Bhanderi? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Bhanderi
Dr. Viralkumar Bhanderi is a medical oncology in Tallahassee, FL, with 19 years in practice. Based on federal Medicare data, Dr. Bhanderi performed 56,066 Medicare services across 1,813 unique beneficiaries.
Between the years covered by Open Payments, Dr. Bhanderi received a total of $9,118 from 76 pharmaceutical and/or device companies across 453 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Bhanderi is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 34% volume in FL$ $9,118 industry payments
Medicare Practice Summary
Medicare Utilization ↗56,066
Medicare services
Top 34% in FL for medical oncology
1,813
Unique beneficiaries
$4
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~2,951 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 45,390 | $0 | $4 |
| Dexamethasone injection (steroid) | 1,810 | $0 | $3 |
| Denosumab injection (Prolia/Xgeva) | 1,620 | $18 | $51 |
| Complete blood count (CBC) with differential | 1,428 | $8 | $29 |
| Blood draw (venipuncture) | 1,343 | $8 | $9 |
| Office visit, established patient (30-39 min) | 884 | $94 | $339 |
| Anti-nausea injection (Aloxi/palonosetron) | 650 | $1 | $28 |
| Anti-nausea injection (ondansetron/Zofran) | 552 | $0 | $9 |
| Administration of chemotherapy into vein, 1 hour or less | 324 | $96 | $378 |
| Drug injection, under skin or into muscle | 260 | $10 | $69 |
| Injection of additional new drug or substance into vein | 209 | $11 | $61 |
| Injection, zoledronic acid, 1 mg | 201 | $6 | $69 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 174 | $22 | $84 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 160 | $46 | $189 |
| Office visit, established patient (20-29 min) | 157 | $56 | $239 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 132 | $1 | $6 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 100 | $25 | $89 |
| Administration of chemotherapy into vein, each additional hour | 88 | $21 | $79 |
| Injection, diphenhydramine hcl, up to 50 mg | 88 | $1 | $3 |
| Administration of additional new drug or substance into vein, 1 hour or less | 62 | $49 | $178 |
| Office visit, established patient, complex (40-54 min) | 60 | $130 | $474 |
| Red blood count automated, with additional calculations | 59 | $5 | $20 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 57 | $3 | $11 |
| Infusion, normal saline solution , 1000 cc | 51 | $2 | $7 |
| Infusion into a vein for hydration, each additional hour | 41 | $10 | $42 |
| Injection of drug or substance into vein | 36 | $27 | $156 |
| Automated urinalysis | 34 | $2 | $8 |
| New patient office visit (45-59 min) | 32 | $122 | $453 |
| New patient office visit, complex (60-74 min) | 21 | $164 | $585 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 19 | $16 | $59 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 12 | $128 | $467 |
| Initial hospital admission, high complexity | 12 | $126 | $556 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
81.7% high complexity
10.9% medium
7.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$9,118
Total received (2018-2024)
Avg $1,303/year across 7 years
Top 47% in FL for medical oncology
76
Companies
453
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,252 (79.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,866 (20.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,595
2023$1,848
2022$1,725
2021$1,062
2020$310
2019$1,343
2018$1,235
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Celgene Corporation
$838
Astellas Pharma US Inc
$771
Novartis Pharmaceuticals Corporation
$656
Genentech USA, Inc.
$509
Boehringer Ingelheim International GmbH
$485
PFIZER INC.
$460
Amgen Inc.
$408
AstraZeneca Pharmaceuticals LP
$340
Janssen Biotech, Inc.
$318
Merck Sharp & Dohme LLC
$254
Ipsen Biopharmaceuticals, Inc
$239
E.R. Squibb & Sons, L.L.C.
$208
Foundation Medicine, Inc.
$200
SEAGEN INC.
$199
GlaxoSmithKline, LLC.
$181
Merck Sharp & Dohme Corporation
$175
Daiichi Sankyo Inc.
$161
Takeda Pharmaceuticals U.S.A., Inc.
$147
SOBI, INC
$127
Pharmacyclics LLC, An AbbVie Company
$117
Incyte Corporation
$115
Octapharma USA, Inc.
$104
BOSTON SCIENTIFIC CORPORATION
$103
GENZYME CORPORATION
$96
ARRAY BIOPHARMA INC
$89
Pharmacosmos Therapeutics Inc.
$88
AMAG Pharmaceuticals, Inc.
$84
Exelixis Inc.
$78
Clovis Oncology, Inc.
$75
AbbVie Inc.
$70
Boehringer Ingelheim Pharmaceuticals, Inc.
$68
Kite Pharma, Inc.
$67
Heron Therapeutics, Inc.
$61
ABBVIE INC.
$59
Secura Bio, Inc.
$53
Blueprint Medicines Corporation
$53
Kyowa Kirin, Inc.
$49
Sysmex Inostics Inc
$45
Regeneron Healthcare Solutions, Inc.
$44
Janssen Pharmaceuticals, Inc
$43
PUMA BIOTECHNOLOGY, INC.
$42
Emmaus Medical, Inc.
$40
Coherus Biosciences Inc.
$39
Pharmacyclics LLC, an AbbVie Company
$39
Lexicon Pharmaceuticals, Inc.
$38
MorphoSys, US Inc.
$38
Lilly USA, LLC
$38
Bayer Healthcare Pharmaceuticals Inc.
$37
Eisai Inc.
$36
Partner Therapeutics, Inc.
$35
CSL Behring
$34
Bayer HealthCare Pharmaceuticals Inc.
$33
Karyopharm Therapeutics Inc.
$32
EMD Serono, Inc.
$28
GE HealthCare
$28
Rigel Pharmaceuticals, Inc.
$22
Array BioPharma Inc.
$22
JAZZ PHARMACEUTICALS INC.
$21
AbbVie, Inc.
$21
G1 Therapeutics, Inc.
$20
BeiGene USA, Inc.
$20
Janssen Scientific Affairs, LLC
$19
CTI BioPharma Corp.
$18
SECURA BIO, INC.
$18
SANOFI-AVENTIS U.S. LLC
$18
Alexion Pharmaceuticals, Inc.
$16
INSYS Therapeutics Inc
$15
Aveo Pharmaceuticals, Inc.
$15
Mirati Therapeutics, Inc.
$14
Apellis Pharmaceuticals, Inc.
$14
Global Blood Therapeutics, Inc.
$14
Seagen Inc.
$14
TG Therapeutics, Inc.
$12
Gilead Sciences, Inc.
$12
NanoString Technologies, Inc.
$11
Sirtex Medical Inc
$7
Top 3 companies account for 24.9% of total payments
Associated products mentioned in payments ›
AYVAKIT · Afstyla · Alecensa · Aliqopa · Avastin · BAVENCIO · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Blincyto · Braftovi · CABLIVI · CABOMETYX · CHANTIX · CINVANTI · COPIKTRA · COSELA · CYRAMZA · Cabometyx · Cinvanti · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ELITEK · ELREXFIO · ENHERTU · ERLEADA · EVENITY · Endari · Enhertu · Erleada · FARESTON · FARYDAK · FERAHEME · FOTIVDA · FOUNDATIONONE · Fabhalta · Farydak · GAVRETO · GAZYVA · GILOTRIF · Herceptin · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · IMJUDO · INJECTAFER · INLYTA · Idelvion · Imbruvica · JAKAFI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · Leukine · MEKINIST · MONJUVI · MONOFERRIC · NERLYNX · NINLARO · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · ONUREG · OPDIVO · OPDUALAG · OXBRYTA · Onivyde · PADCEV · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PROSIGNA ASSAY · Padcev · Phesgo · Polivy · Pomalyst · Poteligeo · Prolia · REBLOZYL · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN LAR · SCEMBLIX · SIR-Spheres Microspheres · SOMATULINE DEPOT · SPRYCEL · SUSTOL · SUTENT · SYNDROS · Somatuline Depot · Stivarga · TAGRISSO · TASIGNA · TECENTRIQ · THERASPHERE · Tavalisse · Tecentriq · UKONIQ · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · VONJO · Venclexta · Vitrakvi · Vonjo · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XALKORI · XARELTO · XPOVIO · XTANDI · Xermelo · Xospata · Xtandi · ZEJULA · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (80%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $16 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
5
Per 100K population
1.7
County median income
$65,074
Nearest hospital
TALLAHASSEE MEMORIAL HEALTHCARE
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Bhanderi is a mixed practice specialist, with moderate Medicare volume, and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Bhanderi experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Bhanderi performed 45,390 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Bhanderi receive payments from pharmaceutical companies?
Yes. Dr. Bhanderi received a total of $9,118 from 76 companies across 453 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Bhanderi's costs compare to other medical oncologys in Tallahassee?
Dr. Bhanderi's average Medicare payment per service is $4. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Bhanderi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Tallahassee
Browse medical oncologys in Tallahassee ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in FL
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in FL
Which FL medical oncologys receive the most from drug and device companies.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology